Newsfeeds - Spark Newswire

4 minute read

Epizyme Late Sunday Announced Strategic Collaboration With HUTCHMED To Develop, Commercialize TAZVERIK In Greater China; Co. Received Upfront $25M Payment, Up To $285M In Potential Milestones

Today, 4:50 PM

Collaboration designed to accelerate global development and investigate TAZVERIK® combinations with HUTCHMED's novel oncology medicines portfolio Epizyme to receive US$25 million upfront payment and up to

EPZM

4 minute read

45 Stocks Moving In Monday’s Mid-Day Session

By Lisa Levin

Today, 4:50 PM

Gainers

ACY

5 minute read

Stocks That Hit 52-Week Lows On Monday

By Benzinga Insights

Today, 4:50 PM

Before 10 a.m. ET Monday, 63 stocks made new 52-week lows.

ACET

2 minute read

12 Health Care Stocks Moving In Monday’s Pre-Market Session

By Benzinga Insights

Today, 4:50 PM

AMTI

1 minute read

Recap: Epizyme Q2 Earnings

By Benzinga Insights

Today, 4:50 PM

Shares of Epizyme (NASDAQ:EPZM) moved higher by 13.3% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share decreased 8.62% year over year to ($0.63), which missed the estimate of ($0.62).

EPZM

1 minute read

Epizyme Q2 EPS $(0.63) Misses $(0.62) Estimate, Sales $13.00M Beat $8.72M Estimate

By Bill Haddad

Today, 4:50 PM

Epizyme (NASDAQ:EPZM) reported quarterly losses of $(0.63) per share which missed the analyst consensus estimate of $(0.62) by 1.61 percent. This is a 8.62 percent decrease over losses of $(0.58) per share from the same

EPZM

3 minute read

20 Stocks Moving in Monday’s Pre-Market Session

By Lisa Levin

Today, 4:50 PM

Gainers Windtree Therapeutics, Inc. (NASDAQ: WINT) shares rose 55.8% to $2.82 in pre-market trading after dropping over 10% on Friday. The company recently reported a wider loss for its second quarter.

ACER

1 minute read

Epizyme Stock Gains On Potential $310M Pact With HUTCHMED For Cancer-Focused Tazverik In Greater China

By Vandana Singh

Today, 4:50 PM

Epizyme Inc (NASDAQ:EPZM) and HUTCHMED (China) Limited (NASDAQ:HCM) have collaborated to research, develop, manufacture, and commercialize Tazverik (tazemetostat) in Greater China, including mainland…

EPZM

14 minute read

Earnings Scheduled For August 9, 2021

By Benzinga Insights

Today, 4:50 PM

Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $1.57 per share on revenue of $215.17 million.

ACM

7 minute read

The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight

By Shanthi Rexaline

Today, 4:50 PM

Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in, triggering stock-specific moves, while clinical readouts also moved stocks during the week.

ABCL